Therapeutics and Vaccines Against Chikungunya Virus
T. Ahola(University of Helsinki), Peter Liljeström(Karolinska Institutet), Mariano Estéban(Consejo Superior de Investigaciones Científicas), Ann M. Powers(Centers for Disease Control and Prevention), Andres Merits(University of Tartu), Pierre Roques(Université Paris-Sud), Marc Lecuit(Inserm), David Hallengärd(Karolinska Institutet), Thérèse Couderc(Inserm), Lisa F. P. Ng(Agency for Science, Technology and Research)
Cited by 70
Related Papers
The trinity of COVID-19: immunity, inflammation and intervention
|Nature reviews. Immunology|2020|4.6k
A Mouse Model for Chikungunya: Young Age and Inefficient Type-I Interferon Signaling Are Risk Factors for Severe Disease
|PLoS Pathogens|2008|610
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
|The Lancet Infectious Diseases|2017|587
Multidisciplinary Prospective Study of Mother-to-Child Chikungunya Virus Infections on the Island of La Réunion
|PLoS Medicine|2008|511
Chikungunya Virus-associated Long-term Arthralgia: A 36-month Prospective Longitudinal Study
|PLoS neglected tropical diseases|2013|494